hotspot -WSS

hotspot

author：comprehensive 2025-09-29 23:28:02 - browse：4865

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Drugmakers bet big on mRNA for cancer. Why's Biden going in?

hotspot

WSS

People can get long Covid without testing positive for virus: Study

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

How to make over

Ebola: Gilead Sciences antiviral shows promise as new treatment

People can get long Covid without testing positive for virus: Study

National associations that represent hospice owe an apology

explore

hotspot

entertainment

Cancer drug shortages should be causing more outrage

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

BioMarin wins approval for gene therapy to treat hemophilia A

First U.S. drug developed to treat liver disease MASH is approved

Bright Health sells Medicare Advantage business to Molina

Boston's new lab space is opening empty

BioMarin wins approval for gene therapy to treat hemophilia A

How to save health care price transparency rules

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why scientists need input from humanists on sensitive research

knowledge

Republicans love RFK Jr. What's that tell us about health in 2024?

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Steward Health Care Massachusetts hospitals face fiscal disaster

Vivek Ramaswamy made waves in the debate, much as in biotech

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Ebola: Gilead Sciences antiviral shows promise as new treatment

focus

Wikipedia

hotspot

hotspot